ATE231491T1 - Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika - Google Patents

Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika

Info

Publication number
ATE231491T1
ATE231491T1 AT96926004T AT96926004T ATE231491T1 AT E231491 T1 ATE231491 T1 AT E231491T1 AT 96926004 T AT96926004 T AT 96926004T AT 96926004 T AT96926004 T AT 96926004T AT E231491 T1 ATE231491 T1 AT E231491T1
Authority
AT
Austria
Prior art keywords
numbing
analgesics
dependence
inhibitor
acquisition
Prior art date
Application number
AT96926004T
Other languages
English (en)
Inventor
Toshitaka Nabeshima
Mitsunobu Yoshii
Tadashi Shiotani
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of ATE231491T1 publication Critical patent/ATE231491T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96926004T 1995-08-07 1996-08-06 Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika ATE231491T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20076395 1995-08-07
PCT/JP1996/002207 WO1997006139A1 (en) 1995-08-07 1996-08-06 Inhibitor for narcotic analgetic dependence/resistance acquisition

Publications (1)

Publication Number Publication Date
ATE231491T1 true ATE231491T1 (de) 2003-02-15

Family

ID=16429771

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926004T ATE231491T1 (de) 1995-08-07 1996-08-06 Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika

Country Status (13)

Country Link
US (1) US6107330A (de)
EP (1) EP0844241B1 (de)
KR (1) KR19990036248A (de)
CN (1) CN1085979C (de)
AT (1) ATE231491T1 (de)
AU (1) AU6631396A (de)
CA (1) CA2228813A1 (de)
DE (1) DE69625913T2 (de)
DK (1) DK0844241T3 (de)
ES (1) ES2191763T3 (de)
NO (1) NO315078B1 (de)
TW (1) TW457087B (de)
WO (1) WO1997006139A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000048847A (ko) * 1996-10-01 2000-07-25 스즈키 다다시 미토콘드리아 막 안정화제
DE69823851D1 (de) * 1997-07-15 2004-06-17 Daiichi Seiyaku Co Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
EP1356812B1 (de) * 2000-12-28 2009-05-13 Hamilton Pharmaceuticals, Inc. Arzneimittel zur behandlung und vermeidung neurogener schmerzen
AU2003273114A1 (en) 2002-10-29 2004-05-25 Sungkyunkwan University Medicament component of berberine for the use of prevention and treatment of psycological dependence on and analgesic tolerance to morphine
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5198317A (en) * 1975-02-21 1976-08-30 22 okisopirorijin 11 iruasetamidochushaekinoseizoho
US4212878A (en) * 1978-01-26 1980-07-15 The Upjohn Company Phenylacetamide derivative analgesics
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4490167A (en) * 1979-08-06 1984-12-25 Ciba-Geigy Corporation Oxime derivatives of diphenyl ethers and their use in herbicidal compositions
BE893276A (fr) * 1981-06-01 1982-11-24 Sandoz Sa Nouvelle application therapeutique d'un derive de l'acetamide
US5468749A (en) * 1988-08-30 1995-11-21 Gawin; Frank H. Method for treatment of substance addiction
IL91451A0 (en) * 1988-08-30 1990-04-29 Bristol Myers Co Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction
US5185329A (en) * 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
DE415693T1 (de) * 1989-08-28 1991-10-17 Arizona Technology Development Corp., Tucson, Ariz. Zusammensetzung und verfahren zur selektiven verstaerkung der opiat-wirkung und verminderung von opiat-toleranz und abhaengigkeit.
US5220018A (en) * 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
IL101514A (en) * 1991-04-10 1996-01-31 Merck & Co Inc Benzodiazepinone derivatives and cholecystokinin antagonist pharmaceutical compositions containing them
JPH0517421A (ja) * 1991-07-10 1993-01-26 Yamanouchi Pharmaceut Co Ltd Ｎ−置換アミド誘導体
FI102748B (fi) * 1992-06-19 1999-02-15 Daiichi Seiyaku Co Menetelmä N-(2,6-dialkyylifenyyli)-2-(2-okso-1-pyrrolidinyyli)asetamid ijohdannaisen valmistamiseksi
US5461157A (en) * 1992-06-19 1995-10-24 Daiichi Pharmaceutical Co., Ltd. Process for preparing pyrrolidinylacetamide derivatives

Also Published As

Publication number Publication date
DE69625913T2 (de) 2003-11-27
DE69625913D1 (de) 2003-02-27
EP0844241B1 (de) 2003-01-22
KR19990036248A (ko) 1999-05-25
WO1997006139A1 (en) 1997-02-20
NO315078B1 (no) 2003-07-07
NO980531L (no) 1998-04-06
NO980531D0 (no) 1998-02-06
AU6631396A (en) 1997-03-05
DK0844241T3 (da) 2003-05-12
EP0844241A1 (de) 1998-05-27
CN1198738A (zh) 1998-11-11
CN1085979C (zh) 2002-06-05
CA2228813A1 (en) 1997-02-20
ES2191763T3 (es) 2003-09-16
EP0844241A4 (de) 1998-11-18
US6107330A (en) 2000-08-22
TW457087B (en) 2001-10-01

Similar Documents

Publication Publication Date Title
EP1072263A4 (de) Amidderivate und nociceptinantagonisten
DK0539117T3 (da) Forbindelser, der er nyttige som leukotrien-antagonister
GR3032083T3 (en) Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
CO5280078A1 (es) Compuestos
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
CA2316902A1 (en) Alpha-aminoamide derivatives useful as analgesic agents
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
BG103863A (en) Indazolamide compounds as serotoninergic forms
DE69104615D1 (de) Diphenylpiperazinderivat.
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
ES2126075T3 (es) Derivados biciclicos nitrogenados como inhibidores de la propil-endopeptidasa.
ATE231491T1 (de) Inhibitor des erwerbs der abhängigkeit/resistenz gegen betäaubende analgetika
EP1314719A4 (de) Benzoesäurederivate und medikamente die diese als aktiven wirkstoff enthalten
ATE207748T1 (de) Hemmung einer fehlentwicklung der ovarien, verspüteter pubertät oder sexuellem infantilismus
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
BG106814A (en) Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals
ES2093091T3 (es) Derivado de glutation.
ATE245447T1 (de) Inhibitor von gehirnödemen
MX9206930A (es) Nuevos compuestos
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
FI904449A0 (fi) N-azasicyklo/3.3.0/oktanamider av aromatiska syror.
ATE158503T1 (de) Aids-virus-infektion hemmende zusammensetzung
EA199800877A1 (ru) Фунгицидные смеси
TR28240A (tr) Amidotiofosfat türevi ve aktif engrediyan olarak bunu iceren insektisid, nematosid ve akarisid.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0844241

Country of ref document: EP

REN Ceased due to non-payment of the annual fee